

## **20.06.2011 - Protocol addendum:**

**Project: Performance of the Ankylosing Spondylitis Disease Activity Score (ASDAS) in patients under biological therapies**

### **Title of the addendum:**

**Predictors of improvement in patients with ankylosing spondylitis receiving anti-TNF**

#### **1. Background of the addendum**

Anti-TNF are indicated in patients with ankylosing spondylitis (AS) who do not have a sufficient response to conventional therapeutic measures, including NSAIDs, and have been proven highly efficacious in reducing symptoms and inflammation.[1, 2]

Predictors of response to therapy may enable improved patient selection, outcomes and resource utilisation. The recommendations for anti-TNF use in AS are, however, based primarily on inadequate response to conventional therapies and less on the expectation that an anti-TNF agent will be effective in a particular patient.[1, 2] The literature continues to establish predictors of response, which are also associated with anti-TNF use in AS. Ideally, these may help clinicians to make evidence-based decisions that maximise the benefits from treatment by targeting subsets of patients most likely to respond; however, single predictors are too weak to be useful for decision-making in the individual patient.[3-10] Anti-TNF treatment is expensive and has potentially serious side effects. Predicting a good response might aid decision-making and improve the benefit/risk ratio in patients selected to start anti-TNF.

#### **2. Aims**

To determine predictors of improvement after 3 and 6 months months of treatment with anti-TNF in anti-TNF-naive patients. Inportantly we aim at analysing prediction of improvement according to the recently developed ASDAS, for which scarce data is available.[11-13]

These aims are in line with the initially submitted research proposal.

### 3. Methods

Data extracted from BioReportEA will be analysed.

Variables will first be selected for univariate logistic regression analyses with 3-month and 6-month response criteria (in particular, ASDAS major improvement and ASDAS clinically important improvement) as the dependent variable.

Age, sex, disease duration, baseline CRP, HLA B27 status, smoking (ever/never), educational level, presence of swollen joints/enthesitis, ASDAS, BASDAI, BASFI and patient global assessments will be considered in univariate analysis.

Relevant variables will then be included in subsequent multivariate logistic regression analysis models, and non-significant variables will be removed from the model one at the time (starting with the least significant variable), checking for confounding, in order to achieve optimal model-fit.

### 4. Research team

- Proponents: Sofia Ramiro, Pedro Machado, Dra Maria José Santos
- Institutions involved: participation is open to all Portuguese centers interested in collaborating in this project. Co-authorship will be granted to a maximum of 4 co-authors per center, actively collaborating in the project
- External consultants: Prof. Robert Landewé, Prof. Désirée van der Heijde, Dr. Astrid van Tubergen (The Netherlands)

### 4. References

1. Braun J, Davis J, Dougados M, Sieper J, van der Linden S, van der Heijde D. First update of the international ASAS consensus statement for the use of anti-TNF agents in patients with ankylosing spondylitis. *Ann Rheum Dis.* 2006 Mar; 65(3):316-320.
2. van der Heijde D, Sieper J, Maksymowych WP, Dougados M, Burgos-Vargas R, Landewe R, et al. 2010 Update of the international ASAS recommendations for the use of anti-TNF agents in patients with axial spondyloarthritis. *Ann Rheum Dis.* 2011 Jun; 70(6):905-908.

3. de Vries MK, van Eijk IC, van der Horst-Bruinsma IE, Peters MJ, Nurmohamed MT, Dijkmans BA, et al. Erythrocyte sedimentation rate, C-reactive protein level, and serum amyloid a protein for patient selection and monitoring of anti-tumor necrosis factor treatment in ankylosing spondylitis. *Arthritis Rheum.* 2009 Nov 15; 61(11):1484-1490.
4. Glintborg B, Ostergaard M, Krogh NS, Dreyer L, Kristensen HL, Hetland ML. Predictors of treatment response and drug continuation in 842 patients with ankylosing spondylitis treated with anti-tumour necrosis factor: results from 8 years' surveillance in the Danish nationwide DANBIO registry. *Ann Rheum Dis.* 2010 Nov; 69(11):2002-2008.
5. Lord PA, Farragher TM, Lunt M, Watson KD, Symmons DP, Hyrich KL. Predictors of response to anti-TNF therapy in ankylosing spondylitis: results from the British Society for Rheumatology Biologics Register. *Rheumatology (Oxford).* 2010 Mar; 49(3):563-570.
6. Rudwaleit M, Claudepierre P, Wordsworth P, Cortina EL, Sieper J, Kron M, et al. Effectiveness, safety, and predictors of good clinical response in 1250 patients treated with adalimumab for active ankylosing spondylitis. *J Rheumatol.* 2009 Apr; 36(4):801-808.
7. Rudwaleit M, Listing J, Brandt J, Braun J, Sieper J. Prediction of a major clinical response (BASDAI 50) to tumour necrosis factor alpha blockers in ankylosing spondylitis. *Ann Rheum Dis.* 2004 Jun; 63(6):665-670.
8. Stone MA, Payne U, Pacheco-Tena C, Inman RD. Cytokine correlates of clinical response patterns to infliximab treatment of ankylosing spondylitis. *Ann Rheum Dis.* 2004 Jan; 63(1):84-87.
9. Vander Cruyssen B, Ribbens C, Boonen A, Mielants H, de Vlam K, Lenaerts J, et al. The epidemiology of ankylosing spondylitis and the commencement of anti-TNF therapy in daily rheumatology practice. *Ann Rheum Dis.* 2007 Aug; 66(8):1072-1077.
10. Visvanathan S, Wagner C, Marini JC, Baker D, Gathany T, Han J, et al. Inflammatory biomarkers, disease activity and spinal disease measures in patients with ankylosing spondylitis after treatment with infliximab. *Ann Rheum Dis.* 2008 Apr; 67(4):511-517.
11. Lukas C, Landewe R, Sieper J, Dougados M, Davis J, Braun J, et al. Development of an ASAS-endorsed disease activity score (ASDAS) in patients with ankylosing spondylitis. *Ann Rheum Dis.* 2009 Jan; 68(1):18-24.
12. Machado P, Landewe R, Lie E, Kvien TK, Braun J, Baker D, et al. Ankylosing Spondylitis Disease Activity Score (ASDAS): defining cut-off values for disease activity states and improvement scores. *Ann Rheum Dis.* 2011 Jan; 70(1):47-53.
13. van der Heijde D, Lie E, Kvien TK, Sieper J, Van den Bosch F, Listing J, et al. ASDAS, a highly discriminatory ASAS-endorsed disease activity score in patients with ankylosing spondylitis. *Ann Rheum Dis.* 2009 Dec; 68(12):1811-1818.